Redeye comments on Faron’s decision to trigger the second €10m tranche of the Heights Capital Manage...
We have updated our investment view on Mendus following its expanded strategy for vididencel to chro...
Redeye comments on CMS’s finalised reimbursement rates, effective from January 2026.
Stayble Therapeutics redovisade ingen nettoomsättning och en minskad rörelseförlust under det tredje...
Redeye provides a short comment on Catella's divestment of Valuation France to Newmark Group, announ...
Flowscape levererar ännu ett kvartal med ett positivt rörelseresultat och en stärkt rörelsemarginal ...
Systemair stod inför fortsatt valutamotvind under hösten, vilket neutraliserade tillväxten och höll ...
* Q3: +24% sales growth, 1.3% adj. EBIT margin * '25e-'27e adj.
Solwers' Q3 sales were in line with our expectation, while EBITA was 8% ahead of our estimate, a cl...
Redeye provides a research update following the Q3 report recently published by Initiator Pharma.
Redeye comments on Heliospectra’s rights issue outcome and has adjusted its fair value range to refl...
Redeye comments on EG7’s letter from Eros Capital which provides further details on the new largest ...
Solwers reported its results for Q3 with sales of EUR 17.
Redeye comments on Lipigon’s Q3 report. The topline readout of the ongoing phase IIa study of Lipise...
HomeMaid redovisade ökad nettoomsättning och EBITA i det tredje kvartalet.
* Strong Q3 production of 2.9kboe/d vs. ABGSCe 2.4kboe/d * '26e EBITDAX up 3% on higher Brage produc...
Redeye comments on the cost savings in IM. The initiative is reasonable and was expected following m...
Redeye provides a research update following the Q3 report published by Cinclus earlier today.
Redeye comments on Cantargia's third quarter report 2025.
Sivers announced a USD3m mass-production order from Tachyon Networks for its 28GHz antenna modules, ...
